Canaccord Genuity Maintains Buy on Adicet Bio, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Adicet Bio (NASDAQ:ACET) with a $19 price target.
August 14, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Adicet Bio with a $19 price target.
The reaffirmation of a Buy rating and a $19 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100